Secondary Hyperparathyroidism
Research on secondary hyperparathyroidism, a condition of elevated parathyroid hormone levels typically caused by chronic kidney disease. Studies evaluate PTH reduction, bone mineral metabolism, and cardiovascular outcomes in dialysis patients.
Quick Answer
What it is
Research on secondary hyperparathyroidism, a condition of elevated parathyroid hormone levels typically caused by chronic kidney disease. Studies evaluate PTH reduction, bone mineral metabolism, and cardiovascular outcomes in dialysis patients.
Key findings
- Grade A: PTH Reduction (Etelcalcetide (Parsabiv))
- Grade A: PTH Target Achievement (Etelcalcetide (Parsabiv))
- Grade A: Serum Calcium (Etelcalcetide (Parsabiv))
Safety
- Effective reduction in serum calcium levels, though hypocalcemia-related adverse events require monitoring and dose adjustment.
ℹ️ Quick Facts
Quick Facts: Secondary Hyperparathyroidism
- Supplements Studied:1
1 supps · 5 outcomes
Detailed Outcomes
A
PTH Reduction
74-75% achieved >30% PTH reduction vs 8-10% placebo. Real-world: median PTH from 636 to 357 pg/mL. Superior to cinacalcet in head-to-head trial.
large↓Improves
A
PTH Target Achievement
Significant increase in patients achieving PTH targets (150-600 pg/mL). Responder rate increased from 27% to 63% in real-world study.
large↑Improves
A
Serum Calcium
Effective reduction in serum calcium levels, though hypocalcemia-related adverse events require monitoring and dose adjustment.
moderate↑Improves
A
Serum Phosphorus
Reduction in serum phosphorus levels observed alongside PTH reduction in clinical trials.
moderate↓Improves
B
FGF23 Levels
Secondary decrease in fibroblast growth factor-23 levels associated with improved mineral metabolism.
moderate↓Improves